An interventional study of Group "chlorhexidine dressing" and Group "solution" in Hemodialysis Catheter Infection, sponsored by Hospital Universitario Marqués de Valdecilla. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-07.
Sponsored by Hospital Universitario Marqués de Valdecilla · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to compare the rate of hemodialysis catheter-related infections according to the treatment regimen: chlorhexidine gluconate dressing or chlorhexidine solution.
Introduction: The use of CVC as a vascular access for haemodialysis is associated with increased morbidity and mortality (up to 10 times higher in a patient with a CVC compared to an arteriovenous fistula), contributing to poorer patient outcomes and increased haemodialysis-related costs.
Aim: To compare the rate of catheter-related infections (bacteraemia, exit site infection and tunelitis) between haemodialysis catheter exit site dressing with 2% chlorhexidine gluconate self-adhesive semi-permeable polyurethane dressings (AGCD); and dressing with 2% chlorhexidine solution and covered with self-adhesive semi-permeable polyurethane dressing (PD).
Methods: A randomized clinical trial will be conducted to compare the occurrence of local and systemic infections related to hemodialysis catheter. Two care groups will be formed in which AGCD and PD dressings will be used. In addition, other clinical variables, patient satisfaction and dressing-related skin alterations will also be analyzed.
Scientific relevance: Infectious complications related with hemodialysis catheter have an increased morbidity, mortality and incremented costs.
Key words: hemodialysis, Central Venous Catheters, Bacteremia, exit site infection, tunnel infection, chlorhexidine gluconate dressing.
Hospital Universitario Marqués de Valdecilla is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CHG Chlorhexidine Gluconate dressing
Device: Group "chlorhexidine dressing"
2% aqueous-based chlorhexidine solution and covering with a semi-permeable self-adhesive polyurethane dressing.
Other: Group "solution"
Cleaning of the exit site with physiological saline (0.9%), drying with sterile gauze, application of semi-permeable polyurethane dressing with self-adhesive 2% chlorhexidine gluconate, centring the chlorhexidine gluconate band well over the exit site.
Cleansing of the exit site with physiological saline (0.9%), drying with sterile gauze, disinfection with 2% aqueous-based chlorhexidine solution, environmental drying for 30 seconds and covering with a semi-permeable self-adhesive polyurethane dressing.
Bacteraemia Rate
presence of fever (body temperature ≥38°C) together with a positive blood culture , with no other source of infection.
Time frame: 3 months
Exit Site Infection Rate
positive culture of pericatheter smear together with presence of inflammatory signs limited to 2 cm around the cutaneous exit site, without upper extension towards the catheter cuff.
Time frame: 3 months
Tunnelitis Rate
occurrence of inflammatory signs extending beyond 2 cm from the cutaneous exit site and into the subcutaneous tract of the catheter (tunnelitis). It may or may not be associated with fever and bacteraemia, and may be accompanied by purulent exudate through the cutaneous exit site.
Time frame: 3 months
Patient Satisfaction Rate
SCALE 18: Degree of perception of positive expectations, of the NOC taxonomy will be used. It will be evaluated using a 5-point Likert-type scale where 1- Not at all satisfied, 2- Somewhat satisfied, 3- Moderately satisfied, 4- Very satisfied, 5- Completely satisfied.
Time frame: 3 months
Percentage of Hemodialysis Sessions With Skin Lesions
They will be assessed at each hemodialysis session, using the NOC taxonomy Skin lesions, by means of the SCALE 14: Degree of a negative or adverse condition or response. A 5-point Likert-type scale will be used, where 1-Severe, 2-Substantial, 3-Moderate, 4-Leve, 5- None.
Time frame: 3 months
Percentage of Hemodialysis Sessions With Dressing-related Skin Erythema Rate
They will be assessed at each hemodialysis session, using the NOC taxonomy Erytema, by means of the SCALE 14: Degree of a negative or adverse condition or response. A 5-point Likert-type scale will be used, where 1-Severe, 2-Substantial, 3-Moderate, 4-Leve, 5- None.
Time frame: 3 months
| Milestone | Group "Chlorhexidine Dressing" | Group "Solution" |
|---|---|---|
| Started | 26 | 27 |
| Completed | 25 | 25 |
| Not completed | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 2 |
presence of fever (body temperature ≥38°C) together with a positive blood culture , with no other source of infection.
| episodes | Control Arm "Group Solution" | Experimental Arm "Chlorhexidine Dressing" |
|---|---|---|
| Bacteraemia Rate | 2 | 1 |
positive culture of pericatheter smear together with presence of inflammatory signs limited to 2 cm around the cutaneous exit site, without upper extension towards the catheter cuff.
| episodes | Group "Chlorhexidine Dressing" | Group "Solution" |
|---|---|---|
| Exit Site Infection Rate | 2 | 12 |
occurrence of inflammatory signs extending beyond 2 cm from the cutaneous exit site and into the subcutaneous tract of the catheter (tunnelitis). It may or may not be associated with fever and bacteraemia, and may be accompanied by purulent exudate through the cutaneous exit site.
| episodes | Group "Chlorhexidine Dressing" | Group "Solution" |
|---|---|---|
| Tunnelitis Rate | 0 | 0 |
SCALE 18: Degree of perception of positive expectations, of the NOC taxonomy will be used. It will be evaluated using a 5-point Likert-type scale where 1- Not at all satisfied, 2- Somewhat satisfied, 3- Moderately satisfied, 4- Very satisfied, 5- Completely satisfied.
| Participants | Group "Chlorhexidine Dressing" | Group "Solution" |
|---|---|---|
| Not at all satisfied | 0 | 0 |
| Somewhat satisfied | 0 | 2 |
| Moderately satisfied | 3 | 1 |
| Very satisfied | 10 | 5 |
| Completely satisfied | 12 | 17 |
They will be assessed at each hemodialysis session, using the NOC taxonomy Skin lesions, by means of the SCALE 14: Degree of a negative or adverse condition or response. A 5-point Likert-type scale will be used, where 1-Severe, 2-Substantial, 3-Moderate, 4-Leve, 5- None.
| percentage of sessions | Group "Chlorhexidine Dressing" | Group "Solution" |
|---|---|---|
| Not Skin Lesions | 99.1 | 99 |
| Skin Lesions | 0.9 | 1 |
They will be assessed at each hemodialysis session, using the NOC taxonomy Erytema, by means of the SCALE 14: Degree of a negative or adverse condition or response. A 5-point Likert-type scale will be used, where 1-Severe, 2-Substantial, 3-Moderate, 4-Leve, 5- None.
| percentage of sessions | Group "Chlorhexidine Dressing" | Group "Solution" |
|---|---|---|
| Not Erythema | 98.2 | 99.2 |
| Erythema | 1.8 | 0.8 |
Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group "Chlorhexidine Dressing" | 0/25 (0%) | 0/25 (0%) | 0/25 (0%) |
| Group "Solution" | 0/25 (0%) | 0/25 (0%) | 0/25 (0%) |
| Age, Continuous(years) | Group "Solution" | Group "Chlorhexidine Dressing" | Total |
|---|---|---|---|
| Mean | 70 ± 13 | 68 ± 15 | 69 ± 15 |
| Sex: Female, Male(Participants) | Group "Solution" | Group "Chlorhexidine Dressing" | Total |
|---|---|---|---|
| Female | 11 | 12 | 23 |
| Male | 14 | 13 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Group "Solution" | Group "Chlorhexidine Dressing" | Total |
|---|---|---|---|
| Hispanic or Latino | 25 | 25 | 50 |
| Not Hispanic or Latino | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Group "Solution" | Group "Chlorhexidine Dressing" | Total |
|---|---|---|---|
| Spain | 25 | 25 | 50 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2020 to primary completion in Jul 2022, 20 months.
Results were first posted in Feb 2024, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Universitario Marqués de Valdecilla